Physician profile
Robert J Dempsey
NPI 1558567644
$1,811.08
in general payments reported to CMS, 2019-2025
27 companies · $36.43 in 2025
The $36.43 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $529 · 2020: $257 · 2021: $131 · 2022: $42.95 · 2023: $405 · 2024: $410 · 2025: $36.43.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $851.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $851.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $385.06 | 2019-2024 | Skyrizi, Viberzi, Duopa |
| Takeda Pharmaceuticals U.S.A., INC. | $310.48 | 2019-2024 | Entyvio, Eohilia |
| Pfizer INC. | $272.24 | 2019-2020 | |
| Janssen Biotech, INC. | $167.35 | 2022-2024 | Stelara, Remicade, Simponi Aria |
| Amag Pharmaceuticals, INC. | $156.41 | 2019-2021 | |
| Shionogi INC | $52.79 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $51.83 | 2019 | |
| Daiichi Sankyo INC. | $40.94 | 2019-2020 | |
| Qol Medical, LLC | $37.84 | 2024 | Sucraid |
| Phathom Pharmaceuticals, INC. | $33.82 | 2024 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $29.59 | 2022-2024 | Dupixent |
| Lilly USA, LLC | $27.50 | 2024 | Omvoh |
| Aimmune Therapeutics, INC. | $21.38 | 2024 | |
| Olympus America INC. | $21.30 | 2025 | Evis Exera III Colonovideoscope |
| Braintree Laboratories, INC. | $19.79 | 2023 | Sutab |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $19.05 | 2023 | Linzess |
| Alexion Pharmaceuticals, INC. | $17.74 | 2019 | |
| Amgen INC. | $17.46 | 2020 | |
| Genzyme Corporation | $17.33 | 2023 | |
| Nestle Healthcare Nutrition INC. | $17.30 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.71 | 2023 | Cyltezo |
| Janssen Pharmaceuticals, INC | $15.13 | 2025 | Invega Trinza, Invega Sustenna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.98 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $12.47 | 2021 | |
| Intercept Pharmaceuticals, INC. | $12.06 | 2020 | |
| Shire North American Group INC | $11.83 | 2019 | |
| Dynavax Technologies Corporation | $10.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Dempsey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.